Significance of CRP and Procalcitonin Level in the Early Diagnosis of Neonatal Sepsis in Erbil, Iraq
Keywords:
Biomarkers, Diagnostic accuracy, Procalcitonin, ROC curveAbstract
Background and Objectives: Neonatal sepsis remains a leading cause of morbidity and mortality in developing countries, where timely diagnosis is challenging. This study aimed to evaluate the diagnostic performance of procalcitonin (PCT) compared with C-reactive protein (CRP) and white blood cell (WBC) count in the early detection of neonatal sepsis in Erbil, Iraq.
Methods: A hospital-based case-control study was conducted in the Raparin Teaching Hospital for Children between April 2023 and October 2024. A total of 80 neonates (40 with culture-confirmed sepsis and 40 controls) were enrolled. Laboratory investigations included complete blood counts, CRP, and PCT measurement. Diagnostic validity indices were calculated, and receiver operating characteristic (ROC) analysis was performed.
Results: PCT levels were significantly higher in septic neonates (773.00 ± 223.01 pg/mL) compared to controls (256.50 ± 137.70 pg/mL, p<0.001). CRP positivity was noted in 36 neonates with sepsis (90.0%) versus 9 controls (22.5%, p=0.002). Mean WBC count was elevated in cases (16.81 ± 2.29 ×10⁹/L) compared to controls (15.15 ± 0.82 ×10⁹/L, p<0.001). CRP demonstrated sensitivity of 90.0% (36/40) and specificity of 77.5% (31/40), while PCT displayed balanced accuracy with sensitivity of 87.5% (35/40) and specificity of 87.5% (35/40). ROC analysis showed the highest discriminatory power for PCT (AUC=0.975, 95% CI: 0.949–0.990), followed by CRP (AUC=0.838) and WBC count (AUC=0.735).
Conclusion: PCT outperformed traditional biomarkers in early diagnosis of neonatal sepsis, providing more balanced diagnostic accuracy. Combining PCT with CRP and clinical assessment may optimize prompt identification and management of sepsis in neonates.
Downloads
References
Kariniotaki C, Thomou C, Gkentzi D, Panteris E, Dimitriou G, Hatzidaki E. Neonatal Sepsis: A Comprehensive Review. Antibiotics. 2025;14(1):6. https://doi.org/10.3390/antibiotics14010006
Attia Hussein Mahmoud H, Parekh R, Dhandibhotla S, Sai T, Pradhan A, Alugula S, et al. Insight Into Neonatal Sepsis: An Overview. Cureus. 2023;15(9):e45530. https://doi.org/10.7759/cureus.45530
Fleischmann C, Reichert F, Cassini A, Horner R, Harder T, Markwart R, et al. Global incidence and mortality of neonatal sepsis: a systematic review and meta-analysis. Archives of disease in childhood. 2021;106(8):745-52. https://doi.org/10.1136/archdischild-2020-320217
Dramowski A, Bolton L, Fitzgerald F, Bekker A. Neonatal Sepsis in Low- and Middle-income Countries: Where Are We Now? The Pediatric infectious disease journal. 2025;44(6):e207-e10. https://doi.org/10.1097/INF.0000000000004815
Umran RM, Hashim JM, Jameel H. Significance of serum procalcitonin level in the early diagnosis of neonatal sepsis. Iranian Journal of Neonatology. 2020;11(3):1-6. https://doi.org/10.22038/ijn.2020.42296.1702
Singh M, Alsaleem M, Gray CP. Neonatal Sepsis. StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Mahdi Alsaleem declares no relevant financial relationships with ineligible companies. Disclosure: Cory Gray declares no relevant financial relationships with ineligible companies.2025.
Boscarino G, Migliorino R, Carbone G, Davino G, Dell’Orto VG, Perrone S, et al. Biomarkers of Neonatal Sepsis: Where We Are and Where We Are Going. Antibiotics. 2023;12(8):1233. https://doi.org/10.1155/2020/8889086
Morad EA, Rabie RA, Almalky MA, Gebriel MG. Evaluation of Procalcitonin, C-Reactive Protein, and Interleukin-6 as Early Markers for Diagnosis of Neonatal Sepsis. International journal of microbiology. 2020;2020:8889086. https://doi.org/10.1155/2020/8889086
9Habib A, Raza S, Ali U, Zubairi AM, Salim E. Diagnostic accuracy of serum procalcitonin (pct) as an early biomarker of neonatal sepsis using blood culture as gold standard. J Coll Physicians Surg Pak. 2021;30(4):383-7. https://doi.org/10.63682/jns.v13i1.8426
Pontrelli G, De Crescenzo F, Buzzetti R, Jenkner A, Balduzzi S, Calò Carducci F, et al. Accuracy of serum procalcitonin for the diagnosis of sepsis in neonates and children with systemic inflammatory syndrome: a meta-analysis. BMC Infectious Diseases. 2017;17(1):302. https://doi.org/10.1186/s12879-017-2396-7
. Shaukat S, Fatima N, Sadiq S, Arif H, Khan M, Khalid R. Procalcitonin Versus C-Reactive Protein: A Comparative Study for the Diagnosis of Neonatal Sepsis. Journal of Saidu Medical College Swat. 2025;15(3):322-8. https://doi.org/10.52206/jsmc.2025.15.3.1036
. Niyoyita JC, Ndayisenga J, Omolo J, Niyompano H, Bimenyimana PC, Dzinamarira T, et al. Factors associated with neonatal sepsis among neonates admitted in Kibungo Referral Hospital, Rwanda. Scientific Reports. 2024;14(1):15961. https://doi.org/10.1038/s41598-024-66818-z
. Rati A, Ratu HA. Meta-analysis of novel biomarkers for early diagnosis of neonatal sepsis. Open access indonesian journal of medical reviews учредители: Hanif medisiana publisher. 2024;4(5):808-21. https://doi.org/10.37275/oaijmr.v4i5.658
. Ahmad R, Liaquat I, Mumtaz N, Zulfiqar S, tul Muntaha S, Rafique N. To Compare Serum Procalcitonin and CRP as Markers of Neonatal Sepsis. Journal of Rawalpindi Medical College. 2024;28(1):1. https://doi.org/10.37939/jrmc.v28i1.2399
. Tum FC, Ngeranwa JJN, Maiyoh GK, Onyambu FG. Validity of procalcitonin and C-reactive protein as biomarkers in diagnosis of neonatal sepsis in a referral hospital, Kenya. Alexandria Journal of Medicine. 2025;61(1):60-6. https://doi.org/10.1080/20905068.2024.2431306
Anugu NR, Khan S. Comparing the Diagnostic Accuracy of Procalcitonin and C-Reactive Protein in Neonatal Sepsis: A Systematic Review. Cureus. 2021;13(11):e19485. https://doi.org/10.7759/cureus.19485
. Hyde E, Anthony M, Kennedy S, Vatish M. Role of complete blood count in the diagnosis of culture-proven neonatal sepsis: a systematic review and meta-analysis. Archives of disease in childhood. 2025;110(10):811. https://doi.org/10.1136/archdischild-2025-328523
. Bagchi NR. A prospective study on reliability and effectiveness of different hematological parameters for early diagnosis of neonatal sepsis in a tertiary care hospital of sub-Himalayan region. Asian Journal of Medical Sciences. 2022;13(11):110-4.
. Shah N, Gandhi H, Mansuriya R, Maru A, Rathod G, Parmar P. Role of Hematological Parameters in the Early Diagnosis of Neonatal Sepsis. Journal of Pharmacy and Bioallied Sciences. 2024;16(1):1. https://doi.org/10.4103/jpbs.jpbs_657_23
Rautela A, Garg J, Agarwal J, Raj N, Das A, Sen M. Evaluation of a novel serum marker, interleukin 27, in comparison to procalcitonin and C-reactive protein in the diagnosis of early-onset neonatal sepsis in a tertiary care center in north India. International Journal of Critical Illness and Injury Science. 2024;14(4):1-11. https://doi.org/10.4103/ijciis.ijciis_45_24
Ruan L, Chen G-Y, Liu Z, Zhao Y, Xu G-Y, Li S-F, et al. The combination of procalcitonin and C-reactive protein or presepsin alone improves the accuracy of diagnosis of neonatal sepsis: a meta-analysis and systematic review. Critical Care. 2018;22(1):316. https://doi.org/10.1186/s13054-018-2236-1
. Sturrock S, Sadoo S, Nanyunja C, Le Doare K. Improving the Treatment of Neonatal Sepsis in Resource-Limited Settings: Gaps and Recommendations. Research and reports in tropical medicine. 2023;14:121-34. https://doi.org/10.2147/RRTM.S410785
De Rose DU, Ronchetti MP, Santisi A, Bernaschi P, Martini L, Porzio O, et al. Stop in Time: How to Reduce Unnecessary Antibiotics in Newborns with Late-Onset Sepsis in Neonatal Intensive Care. Tropical Medicine and Infectious Disease. 2024;9(3):63. https://doi.org/10.3390/tropicalmed9030063.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
